Zogenix Inc (ZGNX) 2.27 $ZGNX
Why Zogenix Inc. Shares Are Feeling the Pain
Sean Williams, The Motley Fool - Motley Fool - Fri May 09, 11:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zogenix , a pharmaceutical company that...
Zogenix Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 3:48PM CDT
Recent Business Highlights
Stock Updates on Health Care Sector Bellwethers -- Research on IMS Health Holdings, Illumina, Novartis, and Zogenix
PR Newswire - Tue May 06, 9:48AM CDT
On Monday, May 05, 2014, the NASDAQ Composite ended at 4,138.06, up 0.34%, the Dow Jones Industrial Average finished the session at 16,530.55, up 0.11% and the S&P 500 closed at 1,884.66, up 0.19%. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, and the index has advanced 0.12% in the previous one month. Investor-Edge has initiated coverage on the following equities: IMS Health Holdings Inc. (NYSE: IMS), Illumina Inc. (NASDAQ: ILMN), Novartis A.G. (NYSE: NVS) and Zogenix Inc. (NASDAQ: ZGNX). Free technical research on IMS, ILMN, NVS and ZGNX can be downloaded upon signing up at:
Zogenix Reports Granting of Inducement Awards
GlobeNewswire - Fri May 02, 3:05PM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to five new non-executive employees.
Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter.
Why Zogenix (ZGNX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:53AM CDT
Zogenix is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month.
Zogenix Announces Conference Call and Webcast to Present First Quarter 2014 Financial Results
GlobeNewswire - Wed Apr 30, 7:31AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the first quarter ended March 31, 2014, after the market closes on Thursday, May 8, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
GlobeNewswire - Thu Apr 24, 6:30AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today that it has entered a definitive agreement to sell its SUMAVEL DosePro Needle-free Delivery System (sumatriptan injection) migraine therapy business to Endo International plc (Nasdaq:ENDP) for $85 million in cash and milestone payments of up to $20 million.
Endo Acquires Rights to Sumavel® DosePro®
PR Newswire - Thu Apr 24, 6:30AM CDT
Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that affiliates of the company have acquired worldwide rights to Sumavel® DosePro® (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc.
A Common Sense Approach to Appropriate Drug Use
PR Newswire - Thu Apr 24, 6:00AM CDT
We at Zogenix have reviewed the letter to Vermont Governor Peter Shumlin signed by the Center for Lawful Access and Abuse Deterrence (CLAAD), The American Academy of Pain Management and the National Fibromyalgia & Chronic Pain Association, which asks the Governor and health commissioner to participate in a "multi-lateral meeting to develop a more thorough approach" to stemming Vermont's prescription drug abuse epidemic. We agree with and commit our support to the fair and consistent approach proposed today. Several states have already adopted more stringent prescriber guidelines and we help educate prescribers on these guidelines as the central focus of our efforts. We would welcome the opportunity to help Vermont implement tighter prescriber guidelines or requirements.
Zogenix Responds to Governor's Action Singling Out Zohydro(TM) ER in Massachusetts, Encourages Officials to Consider Patient Needs and Effective Class-Wide Measures
PR Newswire - Wed Apr 23, 6:30AM CDT
Zogenix will continue to work to ensure patients suffering from severe chronic pain have access to the FDA-approved medications they need in every state nationwide, including Massachusetts. We are once again disappointed that Governor Patrick would issue another immediate restriction without first accepting our offer to discuss the facts and work together to address the needs of patients while combating abuse and addiction.
U.S. District Court Judge Nixes Banning of Zogenix's Painkiller in Massachusetts
ACCESSWIRE - Mon Apr 21, 9:42AM CDT
A U.S. District Court judge stopped Massachusetts from banning the sale of Zogenix Inc.'s (NASDAQ: ZGNX) prescription painkiller Zohydro, saying that the decision was based on the principle that federal law superseded the state's action.
This Week in Biotech: Diabetes Patients Chalk Up 2 Impressive Victories
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 2:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:26PM CDT
If you haven't noticed, earnings season is starting to kick into full swing, and investors apparently like what they're seeing thus far, with the broad-based S&P 500 surging to its third consecutive gain. In addition to a number of positive...
Why Zogenix Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 12:45PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zogenix , a biopharmaceutical company...
Why Zogenix (ZGNX) Stock is Up Today
at The Street - Wed Apr 16, 11:33AM CDT
Zogenix (ZGNX) rose Wednesday after a U.S. District Court stopped Massachusetts from implementing a ban on the pharmaceutical company's prescription painkiller Zohydro. The court ruled federal law superseded the state's ban, which Massachusetts...
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
Why Zogenix Inc. Shares Are Feeling the Pain
Sean Williams, The Motley Fool - Motley Fool - Fri May 09, 11:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zogenix , a pharmaceutical company that...
Zogenix Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 3:48PM CDT
Recent Business Highlights
Stock Updates on Health Care Sector Bellwethers -- Research on IMS Health Holdings, Illumina, Novartis, and Zogenix
PR Newswire - Tue May 06, 9:48AM CDT
On Monday, May 05, 2014, the NASDAQ Composite ended at 4,138.06, up 0.34%, the Dow Jones Industrial Average finished the session at 16,530.55, up 0.11% and the S&P 500 closed at 1,884.66, up 0.19%. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, and the index has advanced 0.12% in the previous one month. Investor-Edge has initiated coverage on the following equities: IMS Health Holdings Inc. (NYSE: IMS), Illumina Inc. (NASDAQ: ILMN), Novartis A.G. (NYSE: NVS) and Zogenix Inc. (NASDAQ: ZGNX). Free technical research on IMS, ILMN, NVS and ZGNX can be downloaded upon signing up at:
Zogenix Reports Granting of Inducement Awards
GlobeNewswire - Fri May 02, 3:05PM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to five new non-executive employees.
Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter.
Why Zogenix (ZGNX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:53AM CDT
Zogenix is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month.
Zogenix Announces Conference Call and Webcast to Present First Quarter 2014 Financial Results
GlobeNewswire - Wed Apr 30, 7:31AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the first quarter ended March 31, 2014, after the market closes on Thursday, May 8, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
GlobeNewswire - Thu Apr 24, 6:30AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today that it has entered a definitive agreement to sell its SUMAVEL DosePro Needle-free Delivery System (sumatriptan injection) migraine therapy business to Endo International plc (Nasdaq:ENDP) for $85 million in cash and milestone payments of up to $20 million.
Endo Acquires Rights to Sumavel® DosePro®
PR Newswire - Thu Apr 24, 6:30AM CDT
Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that affiliates of the company have acquired worldwide rights to Sumavel® DosePro® (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc.
A Common Sense Approach to Appropriate Drug Use
PR Newswire - Thu Apr 24, 6:00AM CDT
We at Zogenix have reviewed the letter to Vermont Governor Peter Shumlin signed by the Center for Lawful Access and Abuse Deterrence (CLAAD), The American Academy of Pain Management and the National Fibromyalgia & Chronic Pain Association, which asks the Governor and health commissioner to participate in a "multi-lateral meeting to develop a more thorough approach" to stemming Vermont's prescription drug abuse epidemic. We agree with and commit our support to the fair and consistent approach proposed today. Several states have already adopted more stringent prescriber guidelines and we help educate prescribers on these guidelines as the central focus of our efforts. We would welcome the opportunity to help Vermont implement tighter prescriber guidelines or requirements.
Zogenix Responds to Governor's Action Singling Out Zohydro(TM) ER in Massachusetts, Encourages Officials to Consider Patient Needs and Effective Class-Wide Measures
PR Newswire - Wed Apr 23, 6:30AM CDT
Zogenix will continue to work to ensure patients suffering from severe chronic pain have access to the FDA-approved medications they need in every state nationwide, including Massachusetts. We are once again disappointed that Governor Patrick would issue another immediate restriction without first accepting our offer to discuss the facts and work together to address the needs of patients while combating abuse and addiction.
U.S. District Court Judge Nixes Banning of Zogenix's Painkiller in Massachusetts
ACCESSWIRE - Mon Apr 21, 9:42AM CDT
A U.S. District Court judge stopped Massachusetts from banning the sale of Zogenix Inc.'s (NASDAQ: ZGNX) prescription painkiller Zohydro, saying that the decision was based on the principle that federal law superseded the state's action.
This Week in Biotech: Diabetes Patients Chalk Up 2 Impressive Victories
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 2:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:26PM CDT
If you haven't noticed, earnings season is starting to kick into full swing, and investors apparently like what they're seeing thus far, with the broad-based S&P 500 surging to its third consecutive gain. In addition to a number of positive...
Why Zogenix Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 12:45PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zogenix , a biopharmaceutical company...
Why Zogenix (ZGNX) Stock is Up Today
at The Street - Wed Apr 16, 11:33AM CDT
Zogenix (ZGNX) rose Wednesday after a U.S. District Court stopped Massachusetts from implementing a ban on the pharmaceutical company's prescription painkiller Zohydro. The court ruled federal law superseded the state's ban, which Massachusetts...
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
